Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry , Bruno Sangro , Thomas Yau +18 more 2017 The Lancet 4168 citations